SCOPUS 정보 검색 플랫폼

Volumn 18, Issue 5, 2012, Pages 466-471

Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis

(4) Chen, Yang Yuan a Yen, Hsu Heng b Chou, Kun Ching b Wu, Shun Sheng b

a CHINA MEDICAL UNIVERSITY HOSPITAL (Taiwan)

b CHANGHUA CHRISTIAN HOSPITAL (Taiwan)

Author keywords

Hepatocellular carcinoma; Thalidomide

Indexed keywords

ALPHA FETOPROTEIN; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; POST TREATMENT SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84863045893 PISSN: 10079327 EISSN: None Source Type: Journal
DOI: 10.3748/wjg.v18.i5.466 Document Type: Review

Times cited : (10)

References (17)

1
- 0141491273
- Hepatocellular carcinoma
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
- (2003) Lancet , vol.362 , pp. 1907-1917
- Llovet, J.M.¹ Burroughs, A.² Bruix, J.³

2
- 84863021779
- Available from
- Taiwan cancer registration report 2007. Available from: URL: http://cph.ntu.edu.tw/
- (2007) Taiwan Cancer Registration Report

3
- 0028332826
- Treatment of hepatocellular carcinoma: Too many options?
- Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12: 1323-1334
- (1994) J Clin Oncol , vol.12 , pp. 1323-1334
- Venook, A.P.¹

4
- 47949116252
- Sorafenib in advanced hepatocellular carcinoma
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
- (2008) N Engl J Med , vol.359 , pp. 378-390
- Llovet, J.M.¹ Ricci, S.² Mazzaferro, V.³ Hilgard, P.⁴ Gane, E.⁵ Blanc, J.F.⁶ de Oliveira, A.C.⁷ Santoro, A.⁸ Raoul, J.L.⁹ Forner, A.¹⁰ Schwartz, M.¹¹ Porta, C.¹² Zeuzem, S.¹³ Bolondi, L.¹⁴ Greten, T.F.¹⁵ Galle, P.R.¹⁶ Seitz, J.F.¹⁷ Borbath, I.¹⁸ Häussinger, D.¹⁹ Giannaris, T.²⁰ more..

5
- 0027286617
- Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography
- Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H. Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography. Hepatology 1993; 17: 1003-1007
- (1993) Hepatology , vol.17 , pp. 1003-1007
- Ikeda, K.¹ Saitoh, S.² Koida, I.³ Tsubota, A.⁴ Arase, Y.⁵ Chayama, K.⁶ Kumada, H.⁷

6
- 0031807538
- Expression of vascular endothelial growth factor in human hepatocellular carcinoma
- Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77
- (1998) Hepatology , vol.28 , pp. 68-77
- Yamaguchi, R.¹ Yano, H.² Iemura, A.³ Ogasawara, S.⁴ Haramaki, M.⁵ Kojiro, M.⁶

7
- 47349113508
- Thalidomide and congenital abnormalities
- McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358
- (1961) Lancet , vol.2 , pp. 1358
- McBride, W.G.¹

8
- 0028216334
- Thalidomide is an inhibitor of angiogenesis
- D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085
- (1994) Proc Natl Acad Sci USA , vol.91 , pp. 4082-4085
- D'amato, R.J.¹ Loughnan, M.S.² Flynn, E.³ Folkman, J.⁴

9
- 0031863851
- Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
- Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Völcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-466
- (1998) Graefes Arch Clin Exp Ophthalmol , vol.236 , pp. 461-466
- Kruse, F.E.¹ Joussen, A.M.² Rohrschneider, K.³ Becker, M.D.⁴ Völcker, H.E.⁵

10
- 0344305652
- Low-dose thalidomide treatment for advanced hepatocellular carcinoma
- Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65: 242-249
- (2003) Oncology , vol.65 , pp. 242-249
- Hsu, C.¹ Chen, C.N.² Chen, L.T.³ Wu, C.Y.⁴ Yang, P.M.⁵ Lai, M.Y.⁶ Lee, P.H.⁷ Cheng, A.L.⁸

11
- 1542790477
- Salvage therapy for hepatocellular carcinoma with thalidomide
- Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 649-653
- (2004) World J Gastroenterol , vol.10 , pp. 649-653
- Wang, T.E.¹ Kao, C.R.² Lin, S.C.³ Chang, W.H.⁴ Chu, C.H.⁵ Lin, J.⁶ Hsieh, R.K.⁷

12
- 10844248554
- Study of thalidomide in patients with unresectable hepatocellular carcinoma
- Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 119-125
- (2005) Cancer , vol.103 , pp. 119-125
- Lin, A.Y.¹ Brophy, N.² Fisher, G.A.³ So, S.⁴ Biggs, C.⁵ Yock, T.I.⁶ Levitt, L.⁷ Phase, I.I.⁸

13
- 0034594628
- New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
- (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
- Therasse, P.¹ Arbuck, S.G.² Eisenhauer, E.A.³ Wanders, J.⁴ Kaplan, R.S.⁵ Rubinstein, L.⁶ Verweij, J.⁷ van Glabbeke, M.⁸ van Oosterom, A.T.⁹ Christian, M.C.¹⁰ Gwyther, S.G.¹¹

14
- 13444303839
- Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial
- Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103: 749-755
- (2005) Cancer , vol.103 , pp. 749-755
- Patt, Y.Z.¹ Hassan, M.M.² Lozano, R.D.³ Nooka, A.K.⁴ Schnirer, I.I.⁵ Zeldis, J.B.⁶ Abbruzzese, J.L.⁷ Brown, T.D.⁸

15
- 37149051789
- Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma
- Yau T, Chan P, Wong H, Ng KK, Chok SH, Cheung TT, Lam V, Epstein RJ, Fan ST, Poon RT. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology 2007; 72 Suppl 1: 67-71
- Oncology 2007; 72 Suppl , vol.1 , pp. 67-71
- Yau, T.¹ Chan, P.² Wong, H.³ Ng, K.K.⁴ Chok, S.H.⁵ Cheung, T.T.⁶ Lam, V.⁷ Epstein, R.J.⁸ Fan, S.T.⁹ Poon, R.T.¹⁰

16
- 33847056761
- Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
- Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol 2007; 46: 234-238
- (2007) Acta Oncol , vol.46 , pp. 234-238
- Chuah, B.¹ Lim, R.² Boyer, M.³ Ong, A.B.⁴ Wong, S.W.⁵ Kong, H.L.⁶ Millward, M.⁷ Clarke, S.⁸ Goh, B.C.⁹

17
- 57749189578
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
- (2009) Lancet Oncol , vol.10 , pp. 25-34
- Cheng, A.L.¹ Kang, Y.K.² Chen, Z.³ Tsao, C.J.⁴ Qin, S.⁵ Kim, J.S.⁶ Luo, R.⁷ Feng, J.⁸ Ye, S.⁹ Yang, T.S.¹⁰ Xu, J.¹¹ Sun, Y.¹² Liang, H.¹³ Liu, J.¹⁴ Wang, J.¹⁵ Tak, W.Y.¹⁶ Pan, H.¹⁷ Burock, K.¹⁸ Zou, J.¹⁹ Voliotis, D.²⁰ Guan, Z.²¹ more..

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.